硅谷银行-2024年健康技术的未来 The Future of Healthtech 2024_第1页
硅谷银行-2024年健康技术的未来 The Future of Healthtech 2024_第2页
硅谷银行-2024年健康技术的未来 The Future of Healthtech 2024_第3页
硅谷银行-2024年健康技术的未来 The Future of Healthtech 2024_第4页
硅谷银行-2024年健康技术的未来 The Future of Healthtech 2024_第5页
已阅读5页,还剩7页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

ReportPreview

ReachouttoyourSVBpointofcontacttogainaccesstothefullversionofthereport.

October2024

ReportPreview

TurningaNewcorner

WelcometoourFutureofHealthtech2024report,acomprehensiveanalysisofchallenges,trendsandopportunitiesintoday’shealthtechinnovationmarket.

Weenteredthisyearwithcautiousoptimism,whichstillringstrueinthethirdquarter.Therearereasonstobeconcerned.Slowerinvestmentpacesand

smallerchecksizesmarkthecurrentinvestmentenvironment.Investorshaveheightenedexpectationsaroundstronguniteconomics,scalabilityandpathstoprofitability.

Normalizationinvaluationsisinfullforce,withvaluationsacrossallstagesunderscrutiny.Atleast12%ofreporteddealsaredownrounds,markingthehighestlevelinthesector’shistory(page9).Therearearecordnumberof

unlabeledandunpricedextensionrounds,wherecompaniesareleaningonexistinginvestorstodelayoravoidavalueadjustment,hopingmarketforces,techinnovationorinvestorconfidencewillletthemgrowintotheir

valuationsbeforetheirrunwayvanishes.However,companiesthatare

strugglingtoraisetheseinsideroundsarehavingtolookatM&A,costcuttinganddownroundsastheircoffersempty,suggestingthe“markdownhammer”hasyettodropfully(page10).

Still,weareinamarkedlydifferentplacethanwewerein2023,andwemaybeturningacorner.Interestrateshavefinallybeguntolower,inflationhascooledslightlyandpublicmarketsremainvolatilebutaregettingstronger.

Thesemacroeconomicimprovementshaveprovidedamuch-neededboosttothespace.Thesharpdropsininvestmenthavetapered,withinvestment

showingsignsofearlyrecovery.Quarterlyinvestmentoverthelastthree

quartersconsistentlyhoveredbetween$4.0Band$4.5B—markedlyhigher

thantheaveragequarterlyinvestmentin2019($3.0B).Early-stagedealactivity

hasgrowntorecordheights(page7),surpassingeven2021levels.

Artificialintelligence(AI)andmachine-learning(ML)techarebringingnew

enthusiasmintothesector,withAIsolutionsachievingstunningtractionandrevenueramprates.Thetransformationisfeltmostinthehealthcareback

office.Virtualassistantsandrevenuecyclemanagementtoolshavetakentheleadininvestmentonthestrengthofclearerrevenuepropositionsandeasierdeployments(page17).Value-basedcare(VBC)hascontinuedtoevolve,as

specialtycarestartupscreatenew,moreintegratedmodelsofcarethatuseAI

foressentialdataanalysisandoutreach(page14).

Despitethesector’stumultuousfewyears,healthtechstartupscontinueto

produceamazinginnovation,frombringingtherighthealthcaretotheright

patientattherighttimetofindingincreasinglybetterwaystosupportprovidersandletthemfocusontheircoremission:helpingpatients.Startupsthatcan

meetthoseneeds,providingmeasurable,provableresultstotheircustomers,

areleadingthehealthtechindustrybacktowardsunnydays.

JulieBettsEbert

ManagingDirector

LifeScience&HealthcareBanking

jbetts@

svb》SBiaiinckonvaiieySource:PitchBookData,Inc.,SVBproprietarydataandSVBanalysis.

ADivisionofFirstcitizensBankTHEFUTUREOFHEALTHTECH2024|2

ADivisionofFirstcitizensBank

THEFUTUREOFHEALTHTECH2024|3

ReportPreview

Fourthemesemergingaboutthefutureofhealthtech

Buildinganewnormal

Growthisslow,but2021isstillweighingthemarketdown.

There’snoendinsightfortheongoing

valuationadjustmentsthroughdownroundsanddealterms.Thatsaid,

investmentamountsandvolumenumbersareshowingappetite

amonginvestorstorebuildandreevaluateportfolios.

Therearemorecompaniesholding

on,hopingnottoneedadownround.Weexpecttoseemorevaluationsfallbutoverallinvestmenttokeeprising.

pleaseexitthroughanywhereatall

Exitsaregettinghardertofindacrosstheboard.

Bigwinnersfrompreviousyears

arenowstrugglingwithinflated

valuationsanddifficultexitpaths.DespitesomesuccessfulrecentIPOs,overallpublichealthtech

performancestilllookspoor.

WithM&Aslowing,investorswillneedtobewillingtogobackto10-or15-

yearhorizonsforhealthtech.

AdministrativeAlisleadingthecharge

ClinicalAIisinthebackseatfornow.

Inthefaceofgrowinguncertaintyabouttheeffectivenessandvalueofclinical

healthAI,administrativeandback-officesolutionsaredrivinginvestmentand

activityinhealthtechAI.

AshealthcarerecoversfromthelastAIhypecycles,clearROIandquantifiableperformancearethemostimportant

factorsinAIdeployments.HealthcareprovidersseemtobecomfortablewithwhereandhowtodeployadministrativeAI.Theydon’tseemtofeelthatway

aboutclinicalAIyet.

valuemmbasedcare

needsintegratedcare

Specialistsaretheboomingfrontierofvalue-basedcare.

There’sagrowingrecognitionthat

coordinationandcollaborationbetweenprimarycareproviders(PCPs)and

specialistsisessentialtomeetingthegoalsofVBCcontracts.

Techthatcanhelpsolvetheproblems

ofdataexchange,patientattributionandcarecoordinationhasavitalroletoplayinthisgrowingecosystem.

svb》SBiaiinckonvaley

ADivisionofFirstcitizensBank

THEFUTUREOFHEALTHTECH2024|4

ReportPreview

TheFutureofHealthtech2024report

Togetthefullreport,reachouttoyourSVBpointofcontact

What’sinside:

svb》SBiaiinckonvaley

ReportPreview

LeadAuthors

JulieBettsEbert

ManagingDirectorLifeScience&

HealthcareBanking

jbetts@

JulieBettsEbertisaManagingDirectoronthe

NationalLifeScience&Healthcareteamat

SiliconValleyBank,coveringtheMid-AtlanticandSoutheastmarkets.Julieprovidesspecialized

bankingservicesanddebt-financingsolutionsandadviceonstrategicgrowthtolifesciencecompaniesacrossallsectorsandlifestages.

JuliereceivedanMBAwithhonorsfromColumbia

BusinessSchoolandaB.S.fromtheMcIntireSchoolofCommerceattheUniversity

ofVirginiawithaconcentrationinfinance.

JackieSpencer

HeadofRelationship

ManagementforLifeScience&HealthcareBanking

jspencer@

JackieSpencerleadstheUSRelationshipManagementteamforLifeScienceand

HealthcareAcceleratorandGrowth.Jackieandherteamarefocusedonprovidingbankingandfinancingsolutionstoinnovativecompaniesinthissector.

SincejoiningSVBin2007,Jackiehasworkedacrossboththetechnologyandhealthcarepracticesfromemergingmarkettolate-stagecorporatefinance.

JackiegraduatedfromSaintMary’sCollegeof

Californiawithhonors,receivingabachelor’sinfinance.

NinaKandilian

SeniorVicePresident

HealthcareVentureCapitalRelationshipManagement

nkandilian@

NinaKandilianmanagesrelationshipswithtraditionalVCfirmsfocusedonhealthcareandlifescience

investments.PriortoSVB,sheledproductmarketingandstrategyatvarioushealthtechstartups

andwaspartofthefoundingteamattheMassChallengeHealthtechstartupacceleratorprogram.NinastartedhercareerattheMassGeneralBrighamhealthsystemin

variousproductanddigitaltransformationroles.

NinareceivedherMBAatBabsonCollegeandabachelor’sdegreefromSuffolkUniversity.

contributors

RaysaBousleiman

VicePresident

HealthcareVentureCapitalRelationshipManagement

rbousleiman@

DennisHe

ManagingDirectorLifeSciences

dhe@

NuziBarkatally

VicePresident

LifeScience&HealthcareStartupBanking

nbarkatally@

BillSideris

Director

LifeScienceandHealthcare

bsideris@

MarketInsightsTeamAuthors

TimotLamarre

Researcher

MarketInsights

tlamarre@

AlexanderLennox-Miller

SeniorResearcherMarketInsights

alennoxmille@

ReportAcknowledgments

Thankyoutothefollowingforlendingtheirsubject-matterexpertisetothisreport:

polarispartnersal6z

svb》SBiaiinckonvaley

5

ADivisionofFirstcitizensBankAllnon-SVBnamedcompaniesareindependentthirdpartiesandarenotaffiliatedwithSiliconValleyBank,adivisionofFirst-CitizensBank&TrustCompany.

ReportPreview

Disclaimers

TheviewsexpressedinthisreportaresolelythoseoftheauthorsanddonotnecessarilyreflecttheviewsofSVB.

Thismaterial,includingwithoutlimitationtothestatisticalinformationherein,isprovidedforinformationalpurposesonly.Thematerialisbasedinpartoninformationfromthird-partysourcesthatwebelievetobereliablebutwhichhasnotbeenindependentlyverifiedbyus,and,assuch,wedonotrepresenttheinformationis

accurateorcomplete.Theinformationshouldnotbeviewedastax,accounting,investment,legalorotheradvice,norisittobereliedoninmakinganinvestmentorotherdecision.Youshouldobtainrelevantandspecificprofessionaladvicebeforemakinganyinvestmentdecision.Nothingrelatingtothematerialshouldbe

construedasasolicitation,offerorrecommendationtoacquireordisposeofanyinvestment,ortoengageinanyothertransaction.

Allnon-SVBnamedcompanieslistedthroughoutthisdocument,asrepresentedwiththevariousstatistical,thoughts,analysisandinsi

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论